Table 3.
Multivariate Cox regression analysis for early-stage IBC patients with HR+.
| Factors | Multivariate analysis | ||||
|---|---|---|---|---|---|
| HR | 95%CI | P | |||
| Lower | Upper | ||||
| Ki67 | <22.50% vs ≥22.50% | 3.601 | 1.395 | 9.298 | 0.008 |
| Chemotherapy | No vs Yes | 3.143 | 1.143 | 8.647 | 0.027 |
| TOP2A | <63.35% vs ≥63.35% | 3.331 | 1.053 | 10.531 | 0.041 |
| HER2 | <65.25% vs ≥65.25% | 7.501 | 2.674 | 21.036 | 0.000 |
IBC, invasive breast cancer; HR, hormonal receptor; HER2, human epidermal growth factor receptor 2; TOP2A, topoisomerase II alpha; HR, hazard ratio; CI, confidence interval. The bolded values present P<0.05.